NSE - Free Realtime Quote INR

Brooks Laboratories Limited (BROOKS.NS)

134.40
-0.49
(-0.36%)
As of 3:22:04 PM GMT+5:30. Market Open.
Loading Chart for BROOKS.NS
  • Previous Close 134.89
  • Open 134.00
  • Bid 134.20 x --
  • Ask 134.40 x --
  • Day's Range 134.00 - 137.90
  • 52 Week Range 73.25 - 198.86
  • Volume 5,085
  • Avg. Volume 63,189
  • Market Cap (intraday) 3.999B
  • Beta (5Y Monthly) 0.73
  • PE Ratio (TTM) --
  • EPS (TTM) -6.99
  • Earnings Date Aug 12, 2025 - Aug 16, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Brooks Laboratories Limited manufactures and sells pharmaceuticals in India and internationally. The company offers liquid and dry powder injection, carbapenem dry powder injectables, tablets, oral suspension, dry syrup, and eye/ear drops. Brooks Laboratories Limited was incorporated in 2002 and is based in Mumbai, India.

www.brookslabs.net

293

Full Time Employees

March 31

Fiscal Year Ends

Recent News: BROOKS.NS

View More

Performance Overview: BROOKS.NS

Trailing total returns as of 5/23/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .

YTD Return

BROOKS.NS
25.39%
S&P BSE SENSEX (^BSESN)
4.60%

1-Year Return

BROOKS.NS
49.50%
S&P BSE SENSEX (^BSESN)
8.38%

3-Year Return

BROOKS.NS
47.33%
S&P BSE SENSEX (^BSESN)
50.56%

5-Year Return

BROOKS.NS
400.70%
S&P BSE SENSEX (^BSESN)
166.47%

Compare To: BROOKS.NS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: BROOKS.NS

View More

Valuation Measures

Annual
As of 5/22/2025
  • Market Cap

    4.01B

  • Enterprise Value

    4.08B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    4.60

  • Price/Book (mrq)

    6.71

  • Enterprise Value/Revenue

    5.33

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -23.54%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    769.62M

  • Net Income Avi to Common (ttm)

    -181.15M

  • Diluted EPS (ttm)

    -6.99

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    8.08M

  • Total Debt/Equity (mrq)

    15.18%

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: BROOKS.NS

View More

Company Insights: BROOKS.NS

Research Reports: BROOKS.NS

View More

People Also Watch